For the Inventor, By the Inventor

Enter assignee name

Hayward, CA, United States of America

Metabolex, Inc.

USPTO Granted Patents = 41

EPO Patents = 5

Trademarks = 1

Forward Citations = 233

Loading Chart...

Loading Chart...

53 inventors (with patents filed for the assignee):

Jeffrey D Johnson (13 out of 117 patents)

Xin Chen (13 out of 20 patents)

Jingyuan Ma (12 out of 19 patents)

4. Zuchun Zhao (11 out of 39 patents)

5. Jiangao Song (9 out of 24 patents)

6. Peng Cheng (8 out of 15 patents)

7. Imad Nashashibi (8 out of 16 patents)

8. Yan Zhu (8 out of 25 patents)

9. Christopher J Rabbat (6 out of 11 patents)

10. Yun-Ping Zhou (6 out of 9 patents)

11. Jian Luo (5 out of 32 patents)

12. John E Blume (5 out of 24 patents)

13. Aaron Robert Novack (5 out of 16 patents)

14. Dong Fang Shi (5 out of 6 patents)

15. John F Palma (5 out of 6 patents)

41 patents: Sort by Forward Citations

1. 8598374 - GPR120 receptor agonists and uses thereof (2013-12-03),

2. 8541614 - Process for the preparation of (−)-(4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester (2013-09-24),

3. 8507719 - Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto (2013-08-13),

4. 8481597 - Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia (2013-07-09),

5. 8476308 - GPR120 receptor agonists and uses thereof (2013-07-02),

6. 8410127 - Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts (2013-04-02),

7. 8354448 - Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetes (2013-01-15),

8. 8329749 - Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia (2012-12-11),

9. 8309600 - GPR120 receptor agonists and uses thereof (2012-11-13),

10. 8299117 - GPR120 receptor agonists and uses thereof (2012-10-30),

11. 8288438 - Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer (2012-10-16),

12. 8288384 - Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders (2012-10-16),

13. 8227495 - 2,4-disubsituted thiazoles and pharmaceutical compositions thereof (2012-07-24),

14. 8203019 - Crystalline solid and amorphous forms of (−)- halofenate and methods related thereto (2012-06-19),

15. 8183381 - N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders (2012-05-22),

Metabolex, Inc. is a leading biopharmaceutical company specializing in the research, development, and commercialization of innovative medicines for metabolic disorders. With a focus on diabetes and related conditions, Metabolex aims to improve the lives of patients through breakthrough therapies. Through cutting-edge research and strategic collaborations, the company is dedicated to creating impactful solutions and advancing healthcare in the realm of metabolic disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

41 Patents

#16 in Hayward, CA

#1,925 in California

#8,156 in US

#16,191 in the World

Hayward, CA, United States of America

Metabolex, Inc.

Forward Citations = 233

53 inventors:

Jeffrey D Johnson (13 out of 117 patents)

Xin Chen (13 out of 20 patents)

Jingyuan Ma (12 out of 19 patents)

4. Zuchun Zhao (11 out of 39 patents)

5. Jiangao Song (9 out of 24 patents)

Please report any incorrect information to support@idiyas.com

Loading…